New cancer clinical trial: Glutaminase Inhibitor CB-839 Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

Published on: February 06, 2019 at 10:30PM

• Tweet
• Share
• Share
• Share
• Share